Biologically Active Small Molecules

A natural monoacylglycerol that is metabolized by monoacylglycerol lipase an agonist of GPR119 (EC₅₀ = 2.5 &microM), stimulating the release of glucagon-like peptide-1 from intestinal L-cells.

A natural monoacylglycerol that is metabolized by monoacylglycerol lipase an agonist of GPR119 (EC₅₀ = 2.5 &microM), stimulating the release of glucagon-like peptide-1 from intestinal L-cells.

An intermediary metabolite of clopidogrel that is converted to an active metabolite via oxidation.

An intermediary metabolite of clopidogrel that is converted to an active metabolite via oxidation.

An intermediary metabolite of clopidogrel that is converted to an active metabolite via oxidation.

A fatty acid ester that potentiates the activity of other endocannabinoids, including 2-AG to bind to CB1 and CB2 and inhibit adenylyl cyclase interacts with endocannabinoids in the modulation of pain sensitivity.

A fatty acid ester that potentiates the activity of other endocannabinoids, including 2-AG to bind to CB1 and CB2 and inhibit adenylyl cyclase interacts with endocannabinoids in the modulation of pain sensitivity.

A fatty acid ester that potentiates the activity of other endocannabinoids, including 2-AG to bind to CB1 and CB2 and inhibit adenylyl cyclase interacts with endocannabinoids in the modulation of pain sensitivity.

A fatty acid ester that potentiates the activity of other endocannabinoids, including 2-AG to bind to CB1 and CB2 and inhibit adenylyl cyclase interacts with endocannabinoids in the modulation of pain sensitivity.

An irreversible, mechanism-based inhibitor of lysine-specific demethylase 1 (LSD1) with an IC50 value of 20.7 &microM and a Ki value of 242.

An irreversible, mechanism-based inhibitor of lysine-specific demethylase 1 (LSD1) with an IC50 value of 20.7 &microM and a Ki value of 242.

A mechanism-based inactivator of human CYP2B6 (Ki = 5.6 &microM IC₅₀ = 5.1 &microM) with potent selectivity for CYP2B6 over other CYP450 isoforms.